Home | Sitemap | Search | Contact A- A A+
   
 
    Public Member Support us  
 

IBCSG 14-93 

AC x 4 followed by CMF x 3 with or without a chemotherapy-free interval, +/- tamoxifen vs. toremifene for post/perimenopausal patients with node positive breast cancer who are not suitable for endocrine therapy alone

DESIGN

Desgin Trial 14-93

Results & Publications


Publications

Study Chairs
Dr. Olivia Pagani - Mendrisio, Switzerland
Dr. Edda Simoncini - Brescia, Italy

Statistician
Shari Gelber

Trial Coordinator
Holly Shaw

Data Managers
Tara Scolese, Dawn Weinbaum

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 836 6097
Email: ibcsg10-15@fstrf.org

Date of Activation
May 1993

Date of Closure
August 1, 1999

Targeted Accrual
884 patients

Final Accrual
969 patients


Results Publications Results & Publications
Other Pathology


News

18.12.2014:
New publications are available 

11.12.2014:
San Antonio Breast Cancer Symposium 2014: IBCSG Presents SOFT Results.

10.12.2014:
IBCSG and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast

All News

 
  Print